University Clinical Centre Tuzla published an updated notice on 14 October 2026 concerning medicines that had not been supplied to the institution by the FBiH Health Insurance Fund by that date. The list includes idarubicin, mitoxantrone, pemetrexed 500 mg, daunorubicin 20 mg and everolimus 10 mg.
The notice reflects the supply situation on the publication date, so availability may change after a new delivery. Patients should confirm the current position with the relevant clinic, hospital pharmacy or clinical team managing their treatment before travelling.
Treatment should not be stopped, changed or postponed without medical advice. Questions about continuing treatment should be discussed with the responsible doctor; this editorial draft does not replace individual medical guidance.